Research
supports
co-testing

Co-testing with Pap and HPV together has consistently and repeatedly identified more cases of precancer and cancer than either Pap or HPV testing alone1,2

A recent retrospective, longitudinal data analysis of 186,000 women between the ages of 30 and 65 found that there is a significantly lower chance of getting a false negative for invasive cervical cancer and precancer with co-testing.1

For the time period of 12 months or more before a diagnosis of cervical cancer:

more women would not have been identified with HPV-alone testing1
more women would not have been identified with Pap-alone testing versus co-testing1

False-negative screening results for invasive cervical cancer

For the time period of 12 months or more before a diagnosis of CIN3+/AIS:

more women would not have been identified with HPV-alone testing1
more women would not have been identified with Pap-alone testing versus co-testing1

False-negative screening results for CIN3+/AIS

An additional national, retrospective analysis of 8.6 million women* ages 30 to 65 comparing Pap-alone testing, HPV-alone testing, and co-testing determined that co-testing finds more cases of CIN3+ vs HPV-alone or Pap-alone testing, reinforcing medical guidelines.2

of women would not have been identified for cervical cancer by screening for HPV alone2

1 in 5 women with cervical cancer would not have been identified by screening for HPV alone2

1 in 16 women with CIN3+ would not have been identified by screening for HPV alone2

*256,648 women received both a co-test (a Pap test and HPV test performed on the same accession) and a cervical cancer biopsy within 1 year2

References
  1. Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150(5):385-392. doi: 10.1093/ajcp/aqy114
  2. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123:282-288. doi: 10.1002/cncy.21544